A retrospective study on 226 polycythemia vera patients: Impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs

Annals of Hematology

Volumn 89, Issue 7, 2010, Pages 691-699

  Crisà, Elena ^a   Venturino, Ermanno ^b   Passera, Roberto ^b   Prina, Marco ^b   Schinco, Piercarla ^a   Borchiellini, Alessandra ^a   Giai, Valentina ^a   Ciocca Vasino, Maria Ausilia ^b   Bazzan, Mario ^c   Vaccarino, Antonella ^c   Boccadoro, Mario ^a   Ferrero, Dario ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

^c Cattedra di Ematologia   (Italy)

Author keywords

Acute myeloid leukemia; Chemotherapy; Hematocrit; Polycythemia vera; Thrombotic events

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BUSULFAN; HYDROXYUREA; PIPOBROMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HEMATOCRIT; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; SURVIVAL; THROMBOSIS; WORLD HEALTH ORGANIZATION; ADOLESCENT; BLOOD; DISEASE FREE SURVIVAL; FOLLOW UP; MIDDLE AGED; MORTALITY; PRACTICE GUIDELINE; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEMATOCRIT; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POLYCYTHEMIA VERA; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOSIS;

EID: 77953068974     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0899-z     Document Type: Article

References (36)

1. Silverstein MN, Lanier AP (1971) Polycythemia vera, 1935- 1969: An epidemiologic survey in Rochester, Minnesota. Mayo Clin Proc 46:751-753
2. Ania BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton LJ 3rd (1994) Trends in the incidence of polycythemia vera among Olmested Country, Minnesota residents, 1935-1989. Am J Hematol 47:89-93
3. Cervantes F, Passamonti F, Barosi G (2008) Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 22:905-914, Epub 2008 Apr 3
4. Kiladjian JJ, Gardin C, Renoux M, Bruno F, Bernard JF (2003) Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. Hematol J 4:198-207
5. Finazzi G, Barbui T (2007) The treatment of polycythaemia vera: An update in the JAK2 era. Intern Emerg Med 2:13-18, Epub 2007 Mar 31
6. Gruppo Italiano Studio Policitemia (1995) Polycythemia vera: The natural history of 1213 patients followed for 20 years. Ann Intern Med 123:656-664
7. Ellis JT, Peterson P, Geller SA, Rappaport H (1986) Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin Hematol 23:144-155
8. Silverstein MN (1976) The evolution into and the treatment of late stage polycythemia vera. Semin Hematol 13:79-84
9. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, Gugliotta L, Landolfi R, Kutti J, Gisslinger H, Marilus R, Patrono C, Pogliani EM, Randi ML, Villegas A, Tognoni G, Barbui T, ECLAP Investigators (2005a) Acute leukemia in polycythemia vera: An analysis of 1638 patients enrolled in a prospective observational study. Blood 105:2664-2670, Epub 2004 Dec 7
10. Berk PD, Goldberg JD, Silverstein MN, Weinfeld A, Donovan PB, Ellis JT, Landaw SA, Laszlo J, Najean Y, Pisciotta AV, Wasserman LR (1981) Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 304:441-447
11. Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.) (1981) Treatment of polycythaemia vera by radiophosphorus or busulphan: A randomized trial. "Leukemia and Hematosarcoma". Br J Cancer 44:75-80
12. Messinezy M, Pearson TC, Prochazka A, Wetherley-Mein G (1985) Treatment of primary proliferative polycythaemia by venesection and low dose busulphan: Retrospective study from one centre. Br J Haematol 61:657-666
13. 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood 89:2319-2327
14. Najean Y, Rain JD, for the French Polycythemia Study Group (1997) Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 90:3370-3377
15. 32P between 1969 and 1981. Semin Hematol 34:6-16
16. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR (1997) From efficacy to safety: A Polycythemia Vera Study Group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 34:17-23
17. Wasserman LR (1986) Polycythemia Vera Study Group: A historical perspective. Semin Hematol 23:183-187
18. McMullin MF, Bareford D, Campbell P, Green AR, Harrison C, Hunt B, Oscier D, Polkey MI, Reilly JT, Rosenthal E, Ryan K, Pearson TC, Wilkins B, General Haematology Task Force of the British Committee for Standards in Haematology (2005) Guidelines for the diagnosis, investigation and management of polycythaemia /erythrocytosis. Br J Haematol 130:174-195 (Pubitemid 41602518)
19. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 110:1092-1097, Epub 2007 May 8
20. Spivak JL, Silver RT (2008) The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: An alternative proposal. Blood 112:231-239, Epub 2008 Apr 9
21. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7:387-397
22. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR, Cancer Genome Project (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054-1061, Erratum in: Lancet 2005;366:122
23. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352:1779-1790 (Pubitemid 40570926)
24. Scott LM, Beer PA, Bench AJ, Erber WN, Green AR (2007) Prevalence of JAK2 V617F and exon 12 mutations in polycythaemia vera. Br J Haematol 139:511-512
25. Skoda R (2007) The genetic basis of myeloproliferative disorders. Hematology, the Education Program of the American Society of Hematology 2007:1-10
26. McMullin MF (2007) A review of the therapeutic agents used in the management of polycythaemia vera. Hematol Oncol 25:58-65
27. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T, European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350:114-124 (Pubitemid 38056222)
28. Finazzi G, Barbui T (2005) Risk-adapted therapy in essential thrombocythemia and polycythemia vera. Blood Rev 19:243-252
29. Finazzi G, Barbui T (2008) Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukemia 22:1494-1502, Epub 2008 Jul 3
30. Di Nisio M, Barbui T, Di Gennaro L, Borrelli G, Finazzi G, Landolfi R, Leone G, Marfisi R, Porreca E, Ruggeri M, Rutjes AW, Tognoni G, Vannucchi AM, Marchioli R, European Collaboration on Lowdose Aspirin in Polycythemia Vera (ECLAP) Investigators (2007) The haematocrit and platelet target in polycythemia vera. Br J Haematol 136:249-259, Epub 2006 Dec 8
31. Vardiman JW, Brunning RD, Harris NL (2001) WHO histological classification of chronic myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization Classification of Tumors: Tumours of the Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer (IARC) Press, Lyon, France, pp 17-44
32. Kiladjian JJ, Chevret S, Dosquet C, Fenaux P, Chomienne C, Rain JD (2008) Long-Term outcome in Polycythemia Vera (PV): final analysis of a randomized trial comparing hydroxyurea (HU) to pipobroman (Pi). Blood (ASH Annual Meeting Abstracts) 112:1746
33. Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T (2005) Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 23:2224-2232, Epub 2005 Feb 14
34. Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, Tognoni G, Marchioli R, European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP) (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 109:2446-2452, Epub 2006 Nov 14
35. Vannucchi AM, Guglielmelli P, Tefferi A (2009) Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin 57:171-191, Apr 15
36. Streiff MB, Smith B, Spivak JL (2002) The diagnosis and management of polycythemia vera in the era since the Polycythemia Vera Study Group: A survey of American Society of Hematology members' practice patterns. Blood 99:1144-1149